| アブストラクト | PURPOSE: To determine whether the use of thiazolidinediones (TZDs) decreases the risk of incident strokes in patients with type 2 diabetes. METHODS: We conducted a nested case-control study within a population-based cohort from the UK General Practice Research Database (GPRD). The cohort comprised patients over the age of 40 who were prescribed a first oral hypoglycemic agent between 1 January 1988 and 30 June 2008. Cases included all subjects who experienced a first stroke during follow-up. Up to 10 controls were matched to each case on age (+/-2 years), sex, date of cohort entry (+/-1 year), and duration of follow-up. Rate ratios (RRs) of stroke associated with TZD use, including rosiglitazone and pioglitazone, relative to combinations of other oral hypoglycemic agents, were estimated using conditional logistic regression. RESULTS: The cohort comprised 75 717 users of oral hypoglycemic agents, of whom 2417 had a stroke during follow-up. The rate of stroke in users of TZDs given as monotherapy (RR: 1.20, 95%CI: 0.77, 1.86) or in combination with other oral hypoglycemic agents (RR: 0.78, 95%CI: 0.58, 1.04) was not lower than combinations of other oral hypoglycemic agents. The RRs were similar for rosiglitazone and pioglitazone. CONCLUSIONS: The results of this study indicate that TZDs do not appear to decrease the incidence of first strokes. |
|---|
| ジャーナル名 | Pharmacoepidemiology and drug safety |
|---|
| Pubmed追加日 | 2009/12/10 |
|---|
| 投稿者 | Azoulay, Laurent; Schneider-Lindner, Verena; Dell'aniello, Sophie; Filion, Kristian B; Suissa, Samy |
|---|
| 組織名 | McGill Pharmacoepidemiology Research Unit, Division of Clinical Epidemiology, Sir;Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/19998318/ |
|---|
